In a recent bid Sensus Healthcare Inc. [SRTS] faced a contemporary bid of $3.70 yielding a 13.00% incline where 35443.0 shares have exchanged hands over the last week. SRTS amount got a boost by 1.37% or $0.05 versus $3.65 at the end of the prior session. This change led market cap to move at 55.99M, putting the price 110.19% below the 52-week high and -25.85% above the 52-week low. The company’s stock has a normal trading capacity of 35443.0 shares while the relative volume is 6.10.
On 8, December 2020, Sensus Healthcare Announces CMS Sets Rates Higher for SRT Reimbursement. According to news published on Yahoo Finance, Centers for Medicare & Medicaid Services sets a 66% increase in reimbursement for Radiation Treatment Delivery code 77401, and increases related Evaluation & Management codes.
Analyst Birdseye View:
The most recent analyst activity for Sensus Healthcare Inc. [NASDAQ:SRTS] stock was on February 14, 2020, when it was Upgrade with a Buy rating from Alliance Global Partners, which also raised its 12-month price target on the stock to $6. Before that, on August 10, 2020, Alliance Global Partners Recapitulated a Buy rating and elevated its amount target to $4.25. On November 07, 2019, B. Riley FBR Downgrade a Neutral rating and plunged its price target on this stock from $14 to $5.50. On January 29, 2019, Northland Capital Downgrade an Under perform rating. On September 26, 2018, B. Riley FBR Initiated a Buy rating and increased its price target to $12.50. On November 03, 2017, Maxim Group Reiterated a Buy rating and boosted its amount target on this stock to $7.50. On June 06, 2017, Maxim Group Initiated a Buy rating and boosted its target amount on this stock to $6.50. On August 08, 2016, Northland Capital Initiated an Outperform rating and improved its amount target to $8.
In the past 52 weeks of trading, this stock has oscillated between a low of $1.76 and a peak of $4.99. Right now, according to Wall Street analyst the average 12-month amount target is $4.43. At the most recent market close, shares of Sensus Healthcare Inc. [NASDAQ:SRTS] were valued at $3.70. According to the average price forecast, investors can expect a potential return of -2.31%.
Sensus Healthcare Inc. [NASDAQ:SRTS] most recently reported quarterly sales of 1.62 billion, which represented growth of -72.40%. This publicly-traded organization’s revenue is $514,401 per employee, while its income is -$32,076 per employee. This company’s Gross Margin is currently 57.60%, its Operating Margin is -53.20%, its Pretax Margin is -6.24, and its Net Margin is -6.24. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -4.84, -6.24, -7.04 and -6.12 respectively.
The Principal structure of this organization shows its whole liability to whole principal at 4.84 and the whole liability to whole assets at 3.86. It shows enduring liability to the whole principal at 3.79 and enduring liability to assets at 0.03 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 3.48 points at 1st support level, the second support level is making up to 3.31. But as of 1st resistance point, this stock is sitting at 3.76 and at 3.86 for 2nd resistance point.
Sensus Healthcare Inc. [SRTS] reported its earnings at -$0.1 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.13/share signifying the difference of 0.03 and 23.10% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.16 calling estimates for -$0.18/share with the difference of 0.02 depicting the surprise of 11.10%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Sensus Healthcare Inc. [NASDAQ:SRTS] is 5.20. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.39. Now if looking for a valuation of this stock’s amount to sales ratio it’s 2.11 and it’s amount to book ratio is 2.08.